You are here: Industry Insights > T2DM

News List

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
April 25, 2025
HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA ACN Newswire
April 16, 2025
HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes Mellitus.
HighTide Therapeutics Announces Publication of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus Open ACN Newswire
March 05, 2025
HighTide Therapeutics announced that Phase 2 data of berberine ursodeoxycholate for treating T2DM was published in JAMA Network Open.
2001 to 2017 Saw Increase in Prevalence of T1DM, T2DM in Youth drugs
August 25, 2021
From 2001 to 2017, there was an increase in the estimated prevalence of type 1 and type 2 diabetes in youth in the United States, according to a study published in the Aug. 24/31 issue of the Journal of the American Medical Association.
ADA: Peds Hospitalization Rates for New-Onset T2DM Up During Pandemic drugs
July 05, 2021
Hospitalization rates for new-onset pediatric type 2 diabetes increased during the COVID-19 pandemic, according to a study presented at the annual meeting of the American Diabetes Association, held virtually from June 25 to 29.
ReShape Announces Positive Preclinical Results for Diabetes Neuromodulation Device americanpharmaceuticalreview
September 17, 2020
ReShape Lifesciences announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study ...
Bariatric Surgery May Aid T2DM-Related Outcomes at Five Years drugs
January 20, 2020
Bariatric surgery is associated with weight loss and remission of type 2 diabetes mellitus (T2DM) and dyslipidemia at five years postsurgery, according to a study published online January in Diabetes, Metabolism Research and Reviews.
Nonalcoholic Steatohepatitis Will Pose Clinical, Economic Burden drugs
January 15, 2020
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus (T2DM), according to a study published online January in Diabetes Care.
Treating Oral Disease Could Yield T2DM-Related Cost Savings drugs
January 06, 2020
Providing nonsurgical periodontal treatment to patients with type 2 diabetes (T2D) and periodontitis may significantly reduce tooth loss and diabetes-related microvascular diseases via improved glycemic control.
T2DM Risk Cut With Weight Loss Even in Nonoverweight People drugs
December 26, 2019
Losing weight is consistently associated with reduced type 2 diabetes risk across body mass index (BMI), family history, and genetic risk categories ...

Previous page 1 2 3 4 Next page